 The treatment of "ETV6" gene-associated solid tumors has not advanced as far as that for "ETV6" gene-associated hematological malignancies.It is proposed that tyrosine kinase inhibitors with specificity for NTRK3's tyrosine kinase activity in "ETV6-NTRK3" gene-associated solid tumors may be of therapeutic usefulness.Entrectinib, a pan-NTRK as well as an ALK and ROS1 tyrosine kinase inhibitor has been found useful in treating a single patient with "ETV6-NRTK3" fusion gene-associated mammary analogue secretory carcinoma and lends support to the clinical development of NTRK3-directed tyrosine kinase inhibitors to treat ETV6-NTRK3 fusion protein associated malignancies.